

GALVmed

Protecting Livestock – Improving Human Lives

GALVmed
Year in Review 2014|15

Foreword

Peter Jeffries,
CEO GALVmed

As we ended another financial year, and the end of my second year as Chief Executive, a number of things struck me...

The progress we made, through the efforts of many, in the relatively short life of GALVmed…

We have a unique mission and very real results can be seen, expressed through the improvements we have recorded in the lives of numerous poor farmers. Our new strategy and business plan to 2021 builds upon this.

The need for constant change and adaptation…

Whether due to civil unrest, drought, endemic diseases or, on a more positive note, successful completion of part of our work, the areas in which we operate require us to be constantly open to changing needs and flexible in the way we oversee our mandate. We need to continue to do this better.

The significant challenges that remain…

However much we can achieve, and however well we do it, I am constantly reminded that GALVmed is but one link in a continuum which involves many others who bring their own skills, from governments and private sector partners, through to individual farmers and vaccinators. True success will come when those benefiting from the work of GALVmed identify how to pick it up themselves at a local level and begin to build on our work without our continued involvement.

But mostly, the quality and level of commitment of our team, whether staff, board or partners…

Whatever we achieve can only be through the commitment of our dedicated staff, many of whom work in challenging conditions to achieve GALVmed's goals, through our extended Board, comprising a wealth of knowledge and experience, who give their time freely to further GALVmed's goals, and through our partners, on whom we rely to fulfil much of the work around our projects.

This review of the past year is testament to the ongoing work and the progress made. As we continue on our mission to deliver significant and sustainable improvements to the lives of poor livestock keepers through improved animal health, I'd like to express my appreciation to all those, past and present, who have made the difference in helping us towards successful completion of our goals.

GALVmed at a Glance

Nearly 900 million of the world's poorest people rely on livestock for their survival. Right now, the widespread loss of animals through disease devastates the lives of individuals, families and communities around the world. In circumstances where poverty or the environment offer no alternatives, chickens, small ruminants, cattle and pigs mean survival, school, clothing, trade and the dignity of choice and self-determination. In spite of the crucial link between animal health and human health, between livestock and livelihood, only 4% of international aid is directed to agricultural needs in developing countries, of which only a small proportion is allocated to livestock.

GALVmed is a not-for-profit livestock health product development & adoption organisation working with and through partners to make livestock vaccines, medicines and diagnostics accessible to the millions for whom livestock is a lifeline. Our focus is on livestock diseases of major economic importance to small-scale livestock producers, including such diseases as East Coast Fever, Newcastle Disease, Contagious Bovine Pleuropneumonia and Peste des Petits Ruminants.

2014/15: The Year in Review

Midway through the second phase of our funding, GALVmed is on track to deliver livestock products to millions of livestock keepers in developing countries. In particular, there has been significant progress towards the delivery of Newcastle disease vaccine targeting village poultry keepers. During the Protecting Livestock phase one (PL1), the Newcastle Disease pilot projects reached tens of thousands of households. Scale-up during PL2 has seen these pilots grow in scale to reach hundreds of thousands of households. And now, a new market initiative with an Indian vaccine manufacturer will see millions of village poultry producing households being reached with the Newcastle Disease vaccine. In the broad field of small-scale agriculture this represents a phenomenally rapid diffusion and uptake of a new technology and is testament to the inherent value of vaccines. This bodes well for the work of GALVmed.

Here are some key highlights for the year in review:

Launch of an upgraded East Coast Fever vaccine production centre in Malawi

The revamped Centre for Ticks and Tick-Borne Diseases was officially launched on 5th December 2014 in celebration of the release of the first batch of vaccine from this new site. The centre is currently producing the East Coast Fever Muguga Cocktail vaccine, which will be distributed to affected East, Central and Southern African countries. The event was attended by Ministers of Agriculture from Malawi, Uganda and Kenya, led by the chief guest, the African Union Commissioner for Rural Economy and Agriculture, Her Excellency Madam Tumusiime Rhoda Peace, amongst other dignitaries and partners.

Enhanced partnerships with private sector to increase delivery of Newcastle Disease vaccine

Since 2008, GALVmed has been working on field pilot projects to prime the market and create the demand for the Newcastle Disease vaccine by backyard poultry keepers of Africa and South Asia. With the success of the pilot projects, GALVmed has been developing some practical processes to scale up delivery in places where vaccine uptake has been successful, collaborating with large-scale private manufacturers and distributors to serve this unique and under-supplied market segment. In India, GALVmed has teamed up with Hester Biosciences Limited to manufacture and distribute a ***thermotolerant Newcastle Disease vaccine.*** This is the first time a major vaccine manufacturer has specifically targeted the village poultry sector as a market segment in its own right. In Uganda, GALVmed is collaborating with Brentec Vaccines International to manufacture and distribute their thermotolerant I-2 Newcastle Disease vaccine.

2014 William Hunting Award honours publication of a paper on development of a low-cost, heat-tolerant Newcastle Disease vaccine tablet

The 2014 William Hunting award was given to a paper “Development of a Low-Dose Fast-Dissolving Tablet Formulation of Newcastle Disease Vaccine for Low-Cost Backyard Poultry Immunisation”. This paper was authored by Dr. Manjari Lal of PATH and was in collaboration with GALVmed, the Southeast Poultry Research Laboratory of the United States Department of Agriculture and the University of Washington.

Bill Gates visits GALVmed

In July 2014, we played host to the co-chair of the Bill & Melinda Gates Foundation, Mr Bill Gates who visited GALVmed for the first time to discuss progress in the development of livestock vaccines and medicines. The meeting brought together some of our key partners, working together as a Global Alliance to develop affordable livestock vaccines, medicines and diagnostics. Mr Gates engaged throughout the meeting at a highly technical level and was very encouraging about the breadth and quality of work being undertaken in the livestock health arena, while emphasising the urgent importance of delivery with impact in improving the lives of poor people. The Bill & Melinda Gates Foundation is one of the principal funders of GALVmed.

Nairobi office established

GALVmed's Africa office opened up for business in July 2014. This is a strategic move to enable better liaisons with our partners across Africa, where most of GALVmed's projects are located. The Nairobi office houses a number of our key staff, including the Market Development and Access department and representatives from the Research & Development and Communications departments.

The opening of the revamped Centre for Ticks and Tick-Borne Diseases in Malawi. The centre is currently producing the Muguga cocktail East Coast Fever vaccine

Developing products for impact

Our Research and Development team works through an extensive network of partners comprising Contract Research Organisations (CROs), commercial and academic laboratories, research institutes and quasi-governmental organisations. The broad focus of GALVmed's R&D work is on the translation of outcomes from basic research through to product development, registration, manufacturing and commercialisation.

Here is a look at some key highlights from the R&D activities for the year:

Initial batches of the East Coast Fever vaccine (ECF-ITM) produced by CTTBD

East Coast Fever (ECF), a protozoal disease of cattle and buffalo, kills more than a million cattle per year in Africa (approximately two cattle every minute) resulting in major economic losses and disempowering vulnerable smallholder livestock farmers. GALVmed, in its mission of improving livelihoods, embarked on a course to support the manufacture and delivery of the East Coast Fever vaccine to farmers.

Our strategy has been to support one commercial manufacturer, the Centre for Ticks and Tick Borne Diseases in Malawi (CTTBD), to produce at least 2.5 million doses of the vaccine by project end (2017). Other partners involved in this strategy include the International Livestock Research Institute (ILRI) in Nairobi, the Directors of Veterinary Services of countries using the Muguga Cocktail (Malawi, Tanzania Kenya and Uganda), and the Pan African Veterinary Vaccine Centre of the Africa Union (AU-PANVAC). A first batch of 375,000 doses were produced by CTTBD in 2014 as a technology transfer batch and released in early 2015, having been tested at ILRI for potency and safety. This batch is currently undergoing field studies to support market authorisation.

A larger second batch of 850,000 doses was produced in December 2014

The second batch has benefitted from cryo-preservative improvements and will have a reduced time from manufacture to release. The successful completion of this second batch was crowned with an official launch of the CTTBD and the vaccine on 5th December 2014 (as noted above). We anticipate that this batch will be released by October 2015. Work is still ongoing with partners – notably CTTBD themselves and U.K. based Arecor - aimed at further product improvements and reduction of manufacturing costs. Similarly, new markets are being sought in other endemic countries.

BEN-1 Project begins

This project has a primary objective of investigating tools for controlling the cattle disease Contagious Bovine Pleuropneumonia (CBPP), a disease with major economic and social impact across large parts of the continent of Africa. Early in 2014 the project began by bringing together the major partners: the Harbin Veterinary Research Institute (HVRI), AU-PANVAC, GALVmed, Central Veterinary Research Institute (CVRI, Zambia), ILRI and Centre de coopération internationale en recherche agronomique pour le développement (CIRAD, France) in an inception meeting. Contracts were established during the year, and work began with the arrival of two visiting HVRI scientists in Debre Zeit, Ethiopia in December 2014. Their main objective was to produce the prototype Chinese BEN-1 strain CBPP vaccine. The laboratory work was done within the premises of AU PANVAC's Process Development Laboratory (PDL), established in collaboration with GALVmed in the Protecting Livestock Project phase one.

In 2015 the vaccines will be produced, quality controlled and field tested. Initially safety will be checked in laboratory animals and cattle in Ethiopia and further work done in a comparative efficacy study at the GALVmed built animal facility at the CVRI in Lusaka, Zambia. Good progress has been made on establishing a clinically relevant contact challenge model for CBPP at CVRI following improvements in culture methodology and challenge procedures.

Tryps Phase 2 project receives new funding to progress work on developing new tools to control African Animal Trypanosomiasis (AAT)

In 2014 the major highlights for the Tryps project have included the awarding of the grant for Tryps Phase 2 ($14.4 Million co-funded by the Bill and Melinda Gates Foundation (BMGF) and the Department for International Aid in the United Kingdom (DFID)). Major partners include Anacor Pharmaceuticals, University of Dundee, Celgene, University of Greenwich, Swiss TPH, Scynexis,University of Glasgow and the Roslin Institute.

In Africa three facilities (Centre International de Recherche-Developpement sur l'Elevage en zone Subhumide (CIRDES) in Burkina Faso, the University of Eduardo Mondlane in Maputo, and Boshoftu at Addis Ababa University) have been upgraded and made fly proof so that clinical trials can be conducted.

Various levels of progress are being made on the three objectives focused on in the previous phases of the tryps project. Progress has been made on novel formulations of the lead candidate for a new therapeutic drug. Additionally the pen-side diagnostic test has been transferred to an external collaborator for optimization in a lateral flow device format.

Testing of samples of trypanocides collected in both informal and formal markets have shown that between 40 – 70% of these products are understrength . This work was completed in two supported laboratories, the Tanzania Food and Drugs Authority (TFDA) in Tanzania and Laboratoire de Contrôle des Médicaments Vétérinaires (LACOMEV) in Senegal.

Rift Valley Fever control tool improvement

Rift Valley Fever (RVF) is a zoonotic disease of ruminants that occurs sporadically and with spectacular impact. Under the Protecting Livestock 1 programme, GALVmed assisted the registration of an RVF vaccine with Onderstepoort Biological Products in South Africa. In the last year a project to improve the shelf-life of this vaccine has begun. The programme seeks to optimise the production and freeze-drying of the attenuated vaccine strain. Once completed, then this work will follow through into combination vaccines containing RVF antigen. A pen-side diagnostic test has been optimised and validated that will allow the rapid diagnosis of RVF infection. Commercialisation discussions with the owner of the technology are ongoing.

Integrated control programmes for Porcine Cysticercosis

GALVmed has collaborated with Professor Marshall Lightowlers (University of Melbourne) for several years to make available an additional control tool for porcine cysticercosis, the encysted stage of the *Taenia solium* lifecycle, which can cause the human disease neuro-cysticercosis which occurs following ingestion of infectious eggs in human faeces. The pig is the intermediate host and is the target of our project to reduce cysts of the tapeworm in meat consumed by humans, thereby breaking the lifecycle of the parasite. The focus of the work is a subunit vaccine based on TSOL-18, which has been scaled up for commercialisation by Indian Immunologicals Limited in Hyderabad. In addition, we are working with M.C.I. Santé Animale of Morocco to make available their oxfendazole product for use in pigs with cysticercosis. The final animal studies have been completed recently to allow submission of a dossier of data for a Marketing Authorisation in India for the TSOL-18 vaccine. Field trials are planned in four countries to demonstrate the benefits on the integrated use of this vaccine and strategic administration of oxfendazole in the reduction of incidence of infectious cysts in pig meat.

Straws of the CTTBD produced East Coast Fever vaccines

Strengthening markets for better access of livestock products

GALVmed's vision is better livestock health contributing to a transformational improvement in the livelihoods of poor livestock keepers. We work towards making effective and affordable vaccines and medicines widely available and used by small-scale farmers in the developing world. Our Market Development and Access team creates the vital link between manufactured products and the farmer. The team works with our partner manufacturers and distributors to ensure livestock health products are made accessible to those who need them most in Africa and South Asia. Part of this process includes registering suitable animal health products in target countries.

Some key activities from our initiatives to make livestock products more accessible to livestock keepers include:

Registration and launch of the Hester Newcastle Disease (ND) vaccine in India

GALVmed has partnered with Hester Biosciences in India to register and launch a thermotolerant Newcastle Disease vaccine. In a joint venture, Hester has recruited a sales team to specifically focus on supplying the needs of the small-scale producer and this vaccine, which is suitable for use in the village setting where refrigeration, key to preserving the viability of a vaccine, is often inadequate, will be the basis for support of this new sales structure. The vaccine is packed in presentations specifically suited to the smaller-scale livestock producer. It is expected that this new product will assist in improving the living standards of individuals in developing countries. The Hester project will realise the vaccinations of more than 100 million chickens in the three Indian states of Chhattisgarh, Jharkhand and Odisha. Over 2,000 vaccinators are currently trained to serve farmers. Hester will create a sustainable distribution network linked with its current network and conduct periodic sero-monitoring for disease surveillance and measuring impact. This initiative will reach up to 5 million households improving their living standards, empowering rural women and improving the nutrition of villagers, especially children. The outcomes and expected successes of this project will encourage Hester and other animal health companies to realise the market potential of the often neglected village poultry production sector often referred to as "backyard poultry". Further developments will see the targeting of village cattle, sheep and goats with appropriate immunisations and medication to improve the production of eggs, milk, meat and wool by controlling the high disease incidences.

Newcastle Disease vaccine production and sales in Uganda

GALVmed has partnered with Brentec Vaccines International of Uganda, who manufacture the thermo-tolerant Newcastle Disease I-2 vaccine, to develop a market distribution system aimed at the village poultry sector. Brentec will produce and distribute over 20 million doses of the I-2 Newcastle Disease vaccine to vaccinate chickens of over 70,000 households in four districts of Uganda.

The Hester and Brentec projects will lead to a dramatic scale-up in Newcastle Disease vaccination levels in village poultry in India and Uganda, building on lessons learnt in earlier pilot projects. The success of these projects will prove the commercial viability of the village poultry production market for suitable animal health solutions and provide significant examples for others to emulate. It will also be a significant step for GALVmed towards handing over a viable solution in the delivery of animal health to the private sector for sustainability. For its part, GALVmed will continue to monitor the projects and provide technical support where required.

Combined sheep & goat pox (SGP) and Peste des petits ruminants (PPR) vaccine

GALVmed is working with M.C.I. Santé Animale of Morocco to test the combined vaccine that will protect small ruminants from SGP and PPR, two highly contagious and deadly viral diseases. The success of the field trials will see the combined vaccine made available commercially to aid in the control and eventual eradication of both diseases in sheep and goats. Preliminary results of the field trials currently ongoing in Mali, Tanzania and Uganda are showing considerable success and mounting interest in the combined vaccine in target countries and international organisations.

Registration of the East Coast Fever vaccine ongoing

The East Coast Fever Infection and Treatment Method (ECF-ITM) vaccine was developed many years ago, but has not been transferred into commercial production. The East Coast Fever Muguga Cocktail, as the vaccine is called, was previously produced by ILRI (the International Livestock Research Institute) near Nairobi, Kenya. With manufacturing transfer to CTTBD, new registration dossiers have been submitted to authorities in Tanzania, Kenya and Uganda, as required to ensure regulatory compliance. The vaccine is registered for use in Malawi. Field trials ongoing in Kenya and Tanzania will support registration efforts in target countries. Early results of the field trials prove the safety of the vaccine.

Effective partnership opens up access of animal health products to rural poor

In South Asia, GALVmed partnered with Heifer International to bring Newcastle Disease vaccination to backyard/village poultry belonging to 100,000 households in the Mayurbhanj district of Orissa, India. As part of this project, 237 vaccinators (mainly women) are currently being trained to undertake vaccinations. In addition, Heifer International is working intensively with 20,000 of the households to improve proper care, feeding, housing and vaccination of backyard/village poultry.



Monitoring and Evaluation

Establishing a Learning Agenda

New adoption clusters set up

The cornerstone of GALVmed's philosophy is that smallholders will pay the market price for vaccines and other essential animal health products. To many economists and development specialists this is a fascinating but challenging proposition. Small-scale agriculture is littered with countless examples of technologies and interventions (e.g. crop varieties, tillage methods, water harvesting techniques) that should have improved production but were not adopted in the field by smallholders. Why should veterinary vaccination be different?

The evidence from the field shows that smallholders willingly pay the market price for vaccines, and do so, on a scale that is measured in millions of doses. This is rational economic behaviour. Vaccines generally cost very little and prevent an economically catastrophic outcome – death of a valued animal. But GALVmed recognises that a Substantial body of learning and evidence still needs to be collected and assessed in this area. What proportion of smallholders are vaccinating and what is the profile of the early adopters? And what of the vaccinators, which perform well and which don't? What are the reasons for these varying degrees of performance? In order to answer these and many other questions, GALVmed has been establishing adoption clusters. These are small representative areas within existing project areas where the necessary data collecting studies can be undertaken.

During the year, 25 Newcastle disease adoption clusters have been established and these will be monitored over the long term to assess vaccine adoption and the underlying trends and patterns behind vaccination. Further adoption clusters are currently being established in East Coast Fever project areas. The body of evidence and the learning agenda established through these adoption clusters will significantly advance our understanding of vaccination in the smallholder context. This will be of great practical value to GALVmed and to our partners, such as vaccine manufacturers and distributors, as we continue to scale-up and expand our market based vaccine initiatives.

The below graphs are derived from GALVmed field data for village poultry projects and are an example of GALVmed's Monitoring & Evaluation (M&E) output. They also clearly demonstrate the basic rationale for GALVmed. Before GALVmed's intervention, there is little spend on vaccination (and other health products) and poultry productivity (as measured by poultry income) is low. After GALVmed's intervention, income has improved significantly while spend on health products (primarily vaccines and de-wormers) has also increased. Therefore the smallholders are substantially better off in terms of their poultry production. Importantly, their increased spending also represents the underlying source of sustainability for vaccination – manufacturers and distributors can see the emergence of a new market segment (the village sector) which they can profitably target, thereby ensuring a sustainable supply.

Poultry keepers spend on vaccines and other health products.

Before



Monthly income from poultry sales(INR)

After



Monthly income from poultry sales(INR)

*INR: Indian Rupee

Supporting policies for good practice

An enabling policy and regulatory environment promotes the sustainable availability, accessibility and adoption of animal health products. The Policy and External Affairs department is tasked with supporting the product and market development objectives of GALVmed. This involves addressing policy related issues through a variety of activities including advocacy. In 2014-15 our policy work centred on understanding key challenges and opportunities and providing smart solutions and partnerships to unlock bottlenecks that impede access to livestock products.

A commercially viable CTTBD

The sustainability of CTTBD as an East Coast Fever-Infection and Treatment Method (ECF-ITM) vaccine manufacturer is dependent on its adoption of an appropriate commercial model. GALVmed continues to provide strategic advice and support to CTTBD to ensure this. GALVmed has assisted in setting up distribution networks for the CTTBD manufactured ECF-ITM vaccine to ensure steady supply in Kenya, Uganda, Malawi and Tanzania where full registration of the vaccine with the respective regulatory authorities is in progress.

Significant progress on vaccine registration harmonisation in East Africa

GALVmed has been working with regional economic communities (RECs) to harmonise the registration of veterinary products. In East African Community (EAC), an approach addressing technical aspects informed by international standards and political aspects focused on achieving political buy in has been adopted. This approach was endorsed by the Council of Ministers of livestock in EAC member states and by the regional summit. This endorsement will require the review of current national laws to align them with the newly harmonised regulations. This will provide an enabling environment for boosting trade and food security within the region. GALVmed will continue with similar activities in other RECs including Economic Community of West African States (ECOWAS) and the Southern African Development Community (SADC).

Understanding the livestock policy landscape and working with partners for greater policy inclusion

Comprehensive policy landscape studies were conducted in Africa and South Asia to understand (i) the impact of livestock emergency interventions on the future of sustainable service delivery and (ii) the policy and practice regarding the role of the private sector and other actors in the delivery of animal health services. These informed the strategic decision to support the appropriate accreditation of community animal health workers (CAHWs). GALVmed held two policy sensitisation workshops with policy makers and thought leaders in Africa (Nairobi, June 2014) and Asia (Delhi, September 2014) with over 60 participants from 13 countries. The meetings endorsed GALVmed-planned activities on supporting the recognition, training and accreditation of CAHWs and developed action plans for country activities. Following from this, GALVmed is working with relevant authorities in India through partners like the South Asia Pro-Poor Livestock Policy Programme, Heifer international, BAIF Development Research Foundation, the Aga Khan Foundation and many others and has provided support in commissioning the drafting of National Occupational Standards (NOS) for veterinary para professionals including CAHWs by the Agriculture Skill Council of India.

As part of our work aimed at facilitating involvement of stakeholders in the policy making review and related processes, GALVmed convened four meetings with 15 leading private sector distributors in East Africa and over 120 farmers including women's groups in Kenya and in Jharkhand, India. These meetings were held in association with partners including BMGF, Agri-Profocus, Kenya Livestock Producer Association (KLPA) and Jharkhand Rural Livelihoods Mission. The workshops aimed at improving active engagement of farmers and the private sector with the policy making processes. A key outcome of the private sector forum was the endorsement of the resolution to establish country based industry associations to advocate for change in policy areas affecting private sector actors in livestock health.

Sharing our knowledge and information

Three databases were established:

(i) The Policy Players database is an open access database of key policy players in Africa and south Asia with 198 records of policy related organisations searchable by country, work area and classification.

(ii) The Livestock Laws and Policies is an open access database with 535 statutes, subsidiary legislation, policies and strategies on livestock from 27 countries.

(iii) The Document Repository database is an open access document repository with GALVmed reports and other documents available for public access. These are in line with our open access knowledge management policy and with that of our donors.

In addition, the free online database of veterinary vaccines (Vetvac) continued to grow and is currently housing 2,600 records on commercially available livestock vaccines found globally. The database is being managed by GALVmed's Portfolio & Contracts team. Between April 2014 and March 2015, over 1,500 records on African, US, UK, French and German markets were updated. Vetvac is useful to researchers, scientists and other professionals working in vaccine development and in the animal health sector generally.

Convening and supporting platforms and initiatives

As part of GALVmed's advocacy work, we co-sponsored initiatives, convenings and platforms that brought together partners and actors in animal health. Among these were the Africa Livestock Conference and Exhibition (ALiCE) in June 2014 in Kampala, the All African Conference on Animal Agriculture (AACAA) in October 2014 in Nairobi and the National Conference on PPR in November 2014 in Delhi. These convenings are part of GALVmed's contribution to advocacy activities in the livestock arena. GALVmed also contributed to the development of Africa's livestock strategy through its involvement in the Guiding Group for the Livestock Development Strategy for Africa (LiDeSA).

Innovative communications for impact

Technology driven awareness campaigns

GALVmed continued to partner with award-winning information and communications technology platform *iCow* to improve livestock farmers' awareness of livestock health solutions including East Coast Fever (ECF) and Newcastle Disease (ND) vaccinations in Kenya. The partnership led to increased farmer's access to information; between March and April 2014, about 29 million impressions (SMS blasts) were sent to farmers on the re-built *Smart Farm Tips* platform. Searches on East Coast Fever and Newcastle Disease products were 55 percent and 22 percent respectively demonstrating increased farmer's awareness of these products. There were increased requests for information from the veterinary "experts" database. The youth accounted for about 55 percent of users accessing the platform. The project allowed for 24/7 user access to information on livestock diseases, stimulating youth engagement in livestock production and contributing to improved productivity and empowerment of rural livestock producers through access to livestock information.



Total number of iCow searches by enterprise category in 2014.

Other partnerships with the Kenya Livestock Producers Association, Shamba Shape Up (local TV programme) and Vetaid (radio programme) to improve awareness on East Coast Fever increased uptake of and demand for ECF-ITM vaccine. The Shamba Shape Up TV programme is viewed by over ten million viewers across East Africa weekly and is based on the rapidly growing rural audience. It aims to give farmers the tools they need to improve productivity and income on their farms. These awareness initiatives along with efforts from our partners on the ground have seen the rise in demand for livestock information, products and services.

GALVmed News launched

GALVmed launched a new look monthly e-newsletter, which features key news from GALVmed and our partners including updates on project implementation. It provides shorter, more succinct and more frequent updates linked to content on our website. Subscribe directly through our website to receive GALVmed News.

Our electronic newsletter was launched late last year

Corporate Services, Finance and Human Resources

As a diverse organisation with an extensive partnership network and a substantial number of associated consultants, GALVmed has a particular requirement for a high degree of administrative effectiveness. A very sizeable itinerary of travelling arrangements, workshop requirements and meeting schedules is maintained and delivered by a small team of administrators. The IT and office accommodation requirements for the three GALVmed sites is also overseen by this administrative team. Their continued commitment and energy will remain a key asset as GALVmed moves ahead with the challenging programme of work in the period ahead.

Within the year GALVmed grew from 27 staff to 36 (including two consultants). In total fourteen people were recruited, including three at director level. Our recruitment process is transparent and aims to optimise diversity. Looking forward, we will be recruiting a further four personnel into new posts to complete our planned number of employees under PL2. By the end of the year, GALVmed had employed staff from 17 nationalities, working in eight countries. In terms of gender, 55% of our staff are women, including three at director level, and nine at manager level.

Some of the GALVmed team members

GALVmed-supported publications over the year

Barbaruah, M.I. & Samad, A. (2014). *Review of the policy, regulatory and administrative framework for delivery of livestock health products and services in South Asia.* GALVmed Policy paper. GALVmed, Edinburgh, UK.

Dhawan, M. & Muraguri, L. (2015). *Summary of findings from two GALVmed Greater Inclusion Workshops.* GALVmed, Edinburgh, UK.

GALVmed. (2015). *East Coast Fever Infection & Treatment Method.* GALVmed position paper. GALVmed, Edinburgh, UK.

Lal, M., Zhu, C., McClurkan, C., Koelle, D.M., Miller, P., Afonso, C., Donadeu M., Dungu, B. & Chen, D. (2014). Development of a low-dose fast-dissolving tablet formulation of Newcastle disease vaccine for low-cost backyard poultry immunisation. *Veterinary Record*, 174.

Luseba, D. (2015). *Review of the policy, regulatory and administrative framework for delivery of livestock health products and services in West and Central Africa.* GALVmed Policy paper. GALVmed, Edinburgh, UK.

Luseba, D. & Rwambo, P. (2015). *Review of the policy, regulatory and administrative framework for delivery of livestock health products and services in Eastern and Southern Africa.* GALVmed Policy paper. GALVmed, Edinburgh, UK.

Nagar, M.D. (2014). Control of PPR disease: Challenges and opportunities. *Proceedings National Conference on PPR Disease.* BAIF Development Research Foundation, India.

Ortiz, P., Terrones, S., Cabrera, M., Ceballos, L., Moreno, L., Canton, C., Donadeu, M., Lanusse, C. & Alvarez, L. (2014). Oxfendazole flukicidal activity in pigs.
Acta Tropica, 136: 10-13.

Tran, T., Napier, G., Rowan, T., Cordel, C., Labuschagne, M., Delespaux, V., Van Reet, N., Erasmus, H., Joubert, A. & Büscher, P. (2014). Development and evaluation of an ITS1 "Touchdown" PCR for assessment of drug efficacy against animal African trypanosomosis. *Veterinary Parasitology*, 202: 164–170.

Wambura, P., Kichuki, M. & Hussein, S.J. (2014). *Promoting access to contagious Caprine Pleuropneumonia (CCPP) vaccine and vaccination in Tanzania: Baseline study in Manyara region.* Report to GALVmed. Edinburgh, UK.

GALVmed

Protecting Livestock – Improving Human Lives

GALVmed UK office

Doherty Building, Pentlands
Science Park
Penicuik, Edinburgh, Scotland
EH26 0PZ
UK

Tel: +44 (0)131 445 6264
Fax: +44 (0)131 445 6222
E-mail: info@galvmed.org
Skype: galvmed

GALVmed Africa office

Galana Plaza, 4th Floor, Wing C,
Suite B
Galana Road, Kilimani
P. O. Box 52773 – 00100
Valley Arcade
Nairobi, Kenya

Tel: +254 (020) 5288627
Tel: +254 (0) 772157782
Email: infonairobi@galvmed.org

GALVmed South Asia office

Unit 118 & 120 B, Splendor Forum
Plot No 3, Jasola District Centre,
Jasola, New Delhi, 110025

Tel: +91 11 40507200
Fax:+91 11 40505993

www.galvmed.org